Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4
- 1 May 2004
- journal article
- clinical trial
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 43 (5) , 877-890
- https://doi.org/10.1053/j.ajkd.2004.01.012
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Use of active vitamin D sterols in patients with chronic kidney disease, stages 3 and 4Kidney International, 2003
- A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidismNephrology Dialysis Transplantation, 1996
- Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failureBMJ, 1995
- Bone Mineral Density Evaluated by Dual-Energy X-Ray Absorptiometry after One-Year Treatment with Calcitriol Started in the Predialysis Phase of Chronic Renal FailureNephron, 1995
- The Use of 1,25-Dihydroxyvitamin D in Early Renal FailureAnnual Review of Medicine, 1992
- Calcium Metabolism in Early Chronic Renal Failure: Implications for the Pathogenesis of HyperparathyroidismNephrology Dialysis Transplantation, 1991
- 1,25(OH)2D3 administration in moderate renal failure: A prospective double-blind trialKidney International, 1989
- Low Dose CalcitriolVersusPlacebo in Patients with Predialysis Chronic Renal Failure*Journal of Clinical Endocrinology & Metabolism, 1988
- Hyperparathyroidism and 1,25-Dihydroxyvitamin D Deficiency in Mild, Moderate, and Severe Renal Failure*Journal of Clinical Endocrinology & Metabolism, 1988
- DETERIORATION OF RENAL FUNCTION DURING TREATMENT OF CHRONIC RENAL FAILURE WITH 1,25- DIHYDROXYCHOLECALCIFEROLThe Lancet, 1978